Claudia Valverde Archives

The drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…

CREATOR: gd-jpeg v1.0 (using IJG JPEG v62), quality = 90

Vall d’Hebron accredited by the Organisation of European Cancer Institutes (OECI) as a Comprehensive Cancer Centre

In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…

Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…